Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
MPM Capital: Congestive heart failure therapeutics developer CHF Solutions will be among first firms to receive investment from $900 mil. MPM BioVentures III fund, considered the largest healthcare venture capital fund raised in 2002 intended for biotechnology and medical technology companies. The fund "will allow us to build and invest for the long term without looking over our shoulders for capital in tough markets," General Partner Nicholas Simon commented in a recent release. MPM will make per-company investments of $5-60 mil. with a middle range of $15-25 mil. in the U.S., Europe and Asia. MPM manages 56 BV III portfolio companies...